中文English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Issue 7
Jul.  2014
Turn off MathJax
Article Contents

Efficacy of antiviral therapy in hepatocellular carcinoma patients with high HBV DNA levels after radical resection

DOI: 10.3969/j.issn.1001-5256.2014.07.021
Research funding:

 

  • Received Date: 2013-11-21
  • Published Date: 2014-07-20
  • Objective To evaluate the efficacy of antiviral therapy in hepatocellular carcinoma (HCC) patients with high HBV DNA levels after radical resection. Methods A retrospective analysis was performed on the clinical data of 113 HCC patients with high HBV DNA levels who underwent radical resection from January 2007 to January 2010. These patients were divided into treatment group (n = 74) and control group (n = 39) . In addition to liver- protecting therapy and supportive care, antiviral therapy was given to the treatment group, but not in the control group. All patients were followed up after operation, and the two groups were compared in terms of HBV DNA level, tumor recurrence rate, and survival rate. Comparison between the two groups was made by t test or chi- square test; the Kaplan- Meier method was used to calculate postoperative survival rates, and the log- rank test was used for survival difference analysis. Results After operation, the treatment group had a continuously decreased HBV DNA level, which was significantly lower at 6, 12, and 24 months after operation than before operation (t = 14. 38, 18. 50, 16. 22, P < 0. 05) ; there were significant differences in HBV DNA levels at 6, 12, and 24 months after operation between the treatment group and control group ( t = 13. 19, 24. 20, 14. 15, P < 0. 05) . The 3- year disease- free survival (DFS) rate showed significant difference between the two groups after operation (P =0.029) . The 1-, 2-, and 3-year cumulative survival rates were 95. 95%, 85. 14%, and 75. 68%, respectively, in the treatment group and 87. 18%, 69. 23%, and 53. 85%, respectively, in the control group; the treatment group had a significantly higher 3- year cumulative survival rate than the control group (P = 0. 016) .Conclusion Antiviral therapy can increase 3- year DFS rate and prolong postoperative survival in HCC patients with high HBV DNA levels after radical resection. Thus, antiviral therapy should be performed early, regularly, and persistently in HCC patients with high HBV DNA levels.

     

  • loading
  • [1] YUEN MF, HOU JL, CHUTAPUTTI A.Hepatocellular carcinoma in the Asia pacific region[J].J Gastroenterol Hepatol, 2009, 24 (3) :346-353.
    [2]LIN H, VAN DEN ESSCHERT J, LIU C, et al.Systematic review of hepatocellular adenoma in China and other regions[J].J Gastroenterol Hepatol, 2011, 26 (1) :28-35.
    [3]YUN FL, J HK, TEERHA PIRATVISUTH, et al.Asian-pacific consensus statement on the management of chronic hepatitis B:a2012 update[J].J Clin Hepatol, 2012, 28 (8) :641-661. (in Chinese) 亚太肝病学会慢性乙型肝炎治疗共识工作组.亚太地区慢性乙型肝炎治疗共识 (2012最新版) [J].临床肝胆病杂志, 2012, 28 (8) :641-661.
    [4]HAN Y, ZHU JY.Risk factor's survelliance and treatment for hepatocellular carcinoma in cirrhosis[J].Chin J Pract Intern Med, 2013, 33 (9) :694-697. (in Chinese) 韩英, 朱疆依.肝硬化并发肝癌危险因素筛查及综合治疗[J].中国实用内科杂志, 2013, 33 (9) :694-697.
    [5]WANG YH, LIU YX.Tumor staging scheme, radical resection criterion and prognostic index of preimary liver cancer[J].Chin J Hepatobiliary Surg, 2003, 9 (1) :3-7. (in Chinese) 王悦华, 刘永雄.原发性肝癌的分期、根治切除标准及预后指标[J].中华肝胆外科杂志, 2003, 9 (1) :3-7.
    [6]CHUMA M, HIGE S, KAMIYAMA T, et al.The influence of hepatitis B DNA level and antiviral therapy on recurrence after initial curative treatment in patients with hepatocellular carcinoma[J].J Gastroenterol, 2009, 44 (9) :991-999.
    [7]ISHIKAWA T.Clinical features of hepatitis B virus-related hepatocellular carcinoma[J].World J Gastroenterol, 2010, 16 (20) :2463-2467.
    [8] CHEN CJ, YANG HI, LLOEJE UH.Hepatitis B virus DNA levels and outcomes in chronic hepatitis B[J].Hepatology, 2009, 49 (Suppl 5) :s72-s84.
    [9] HUANG L, LI J, LAU WY, et al.Perioperative reactivation of hepatitis B virus replication in patients undergoing partial hepatectomy for hepatocellular carcinoma[J].J Gastroenterol Hepatol, 2012, 27 (1) :158-164.
    [10] WU CY, CHEN YJ, HO HJ, et al.Association between nucleoside analogues and risk of hepatitis B virus-related hepatocellular carcinoma recurrence following liver resection[J].JAMA, 2012, 308 (18) :1906-1913.
    [11]GUO XP, LIU YW, WANG W, et al.Treatment of liver cirrhosis with postoperative hepatocellular carcinoma with nucleoside analog[J].J Clin Hepatol, 2010, 26 (4) :425-427. (in Chinese) 郭西萍, 刘彦威, 王婉, 等.核苷类抗病毒治疗伴活动性肝硬化肝癌术后的临床观察[J].临床肝胆病杂志, 2010, 26 (4) :425-427.
    [12]LI GS, LIU GH, ZHEN H.Application value of antiviral therapy for liver cancer patients infected with hepatitis B virus undergoing radical resection[J].Chin J Gen Surg, 2013, 22 (7) :880-884. (in Chinese) 李巨仕, 刘国华, 郑核.抗病毒治疗对行根治切除术肝癌合并乙肝病毒感染患者的应用价值[J].中国普通外科杂志, 2013, 22 (7) :880-884.
    [13]GOU W, WANG YL.Clinical efficacy of entecavir in treatment of hepatogenous diabetes[J].J Clin Hepatol, 2013, 29 (6) :456-458. (in Chinese) 苟卫, 王燕玲.恩替卡韦治疗乙型肝炎肝硬化合并肝源性糖尿病的临床观察[J].临床肝胆病杂志, 2013, 29 (6) :456-458.
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Article Metrics

    Article views (2382) PDF downloads(570) Cited by()
    Proportional views
    Related

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return